Thanatophoric Dysplasia Medication

1. Martínez-Frías ML, Egüés X, Puras A, Hualde J, de Frutos CA, Bermejo E, et al. Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly: Insights into its pathogenesis. Am J Med Genet A. 2011 Jan. 155A(1):197-202. [QxMD MEDLINE Link].

2. Naveen NS, Murlimanju BV, Kumar V, Pulakunta T. Thanatophoric dysplasia: a rare entity. Oman Med J. 2011 May. 26(3):196-7. [QxMD MEDLINE Link]. [Full Text].

3. Martin L, Kaci N, Estibals V, et al. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia. Hum Mol Genet. 2018 Jan 1. 27 (1):1-13. [QxMD MEDLINE Link].

4. Jung M, Park SH. Genetically confirmed thanatophoric dysplasia with fibroblast growth factor receptor 3 mutation. Exp Mol Pathol. 2017 Apr. 102 (2):290-5. [QxMD MEDLINE Link]. [Full Text].

5. Baker KM, Olson DS, Harding CO, Pauli RM. Long-term survival in typical thanatophoric dysplasia type 1. Am J Med Genet. 1997 Jun 27. 70(4):427-36. [QxMD MEDLINE Link].

6. MacDonald IM, Hunter AG, MacLeod PM, MacMurray SB. Growth and development in thanatophoric dysplasia. Am J Med Genet. 1989 Aug. 33(4):508-12. [QxMD MEDLINE Link].

7. Nikkel SM, Major N, King WJ. Growth and development in thanatophoric dysplasia - an update 25 years later. Clin Case Rep. 2013 Dec. 1 (2):75-8. [QxMD MEDLINE Link]. [Full Text].

8. Carroll RS, Duker AL, Schelhaas AJ, Little ME, Miller EG, Bober MB. Should We Stop Calling Thanatophoric Dysplasia a Lethal Condition? A Case Report of a Long-Term Survivor. Palliat Med Rep. 2020. 1 (1):32-9. [QxMD MEDLINE Link]. [Full Text].

9. Ushioda M, Sawai H, Numabe H, Nishimura G, Shibahara H. Development of individuals with thanatophoric dysplasia surviving beyond infancy. Pediatr Int. 2022 Jan. 64 (1):e15007. [QxMD MEDLINE Link]. [Full Text].

10. Cohen MM Jr. Cloverleaf skulls: etiologic heterogeneity and pathogenetic variability. J Craniofac Surg. 2009 Mar. 20 Suppl 1:652-6. [QxMD MEDLINE Link].

11. Chitty LS, Mason S, Barrett AN, et al. Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach. Prenat Diagn. 2015 Jul. 35 (7):656-62. [QxMD MEDLINE Link].

12. [Guideline] Cunniff C. Prenatal screening and diagnosis for pediatricians. Pediatrics. 2004 Sep. 114(3):889-94. [QxMD MEDLINE Link].

13. Blaas HG, Vogt C, Eik-Nes SH. Abnormal gyration of the temporal lobe and megalencephaly are typical features of thanatophoric dysplasia and can be visualized prenatally by ultrasound. Ultrasound Obstet Gynecol. 2012 Feb 28. [QxMD MEDLINE Link].

14. Wang L, Takai Y, Baba K, et al. Can biparietal diameter-to-femur length ratio be a useful sonographic marker for screening thanatophoric dysplasia since the first trimester? A literature review of case reports and a retrospective study based on 10,293 routine fetal biometry measurements. Taiwan J Obstet Gynecol. 2017 Jun. 56 (3):374-8. [QxMD MEDLINE Link]. [Full Text].

15. Wang DC, Shannon P, Toi A, et al. Temporal lobe dysplasia: a characteristic sonographic finding in thanatophoric dysplasia. Ultrasound Obstet Gynecol. 2014 Nov. 44 (5):588-94. [QxMD MEDLINE Link].

16. Ulla M, Aiello H, Cobos MP, Orioli I, García-Mónaco R, Etchegaray A, et al. Prenatal diagnosis of skeletal dysplasias: contribution of three-dimensional computed tomography. Fetal Diagn Ther. 2011. 29(3):238-47. [QxMD MEDLINE Link].

Germaine L Defendi, MD, MS, FAAP Associate Clinical Professor, Department of Pediatrics, Olive View-UCLA Medical Center

Germaine L Defendi, MD, MS, FAAP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Luis O Rohena, MD, PhD, FAAP, FACMG Deputy Chief, Department of Pediatrics, Chief, Medical Genetics, San Antonio Military Medical Center; Associate Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Professor of Pediatrics, University of Texas Health Science Center at San Antonio

Luis O Rohena, MD, PhD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors M Carter, MS, and Susan J Gross, MD, FRCS(C), FACOG, FACMG, to the original writing and development of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article